Vaxcyte Shares Surge As Its Pneumococcal Vaccine On Par With Pfizer's Shot In Study

  • Vaxcyte Inc PCVX announced positive topline results from the Phase 1/2 proof-of-concept study evaluating VAX-24, the company's investigational 24-valent pneumococcal conjugate vaccine (PCV), in healthy adults aged 18-64. 
  • VAX-24 met the primary safety and tolerability objectives, demonstrating a safety profile similar to Pfizer Inc's PFE Prevnar 20 (PCV20) for all doses studied.
  • In the study, VAX-24 met or exceeded the established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2mcg dose, which the company intends to move forward into a Phase 3 program. 
  • At this dose, VAX-24 met the standard opsonophagocytic activity (OPA) response non-inferiority criteria for all 20 serotypes common with PCV20, of which 16 achieved higher immune responses. 
  • Additionally, at all three doses, VAX-24 met the standard superiority criteria for all four serotypes unique to VAX-24. These four incremental serotypes cover 10-15 percent of strains causing invasive pneumococcal disease (IPD) over the current standard of care in adults.
  • VAX-24 demonstrated a safety and tolerability profile similar to PCV20 at all doses studied.
  • The full six-month safety follow-up is ongoing for the Phase 2 portion of the study. Final results are anticipated in 1H of 2023.
  • Price Action: PCVX shares are up 71% at $35.18 on the last check Monday.


Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!